Phase 2 Study of KHK7580

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This randomized, placebo-controlled, double-blind (included open arm of KRN1493 (cinacalcet)), parallel-group, multi-center study is designed to evaluate efficacy and safety in cohorts comprising KHK7580, its placebo and KRN1493 (cinacalcet) orally administered for three weeks for secondary hyperparathyroidism patients receiving hemodialysis.
Epistemonikos ID: af7c2bd41a9c627d9991794a0a56eb0c52e56f5a
First added on: May 12, 2024